Hepatitis C Main Section
FDA-approved Monotherapies
FDA-approved Combination Therapies
Intron A
Roferon

Infergen
Pegasys
PEG-Intron
Pegasys + Copegus
PEG-Intron + Rebetol
Intron A + Rebetol
Roferon A + Ribavirin
Link to Hepatitis C Main Section

Sustained Viral Response (SVR)
/ Rapid Virologic Response (RVR)
/ Early Viral Response (EVR)
/ End of Treatment Response (EOT)

Duration of Pegylated Interferon plus Ribavirin May Be Tailored Based on Early Response - 1/04/08

Induction with High-dose Pegylated Interferon alfa-2a (Pegasys) Is More Effective than Standard Dosing for Achieving Rapid and Early Virological Response: The CHARIOT Study - 11/20/07

Virological Response
and Safety Outcomes in Chronic Hepatitis C Patients Treated with Pegylated Interferon plus Taribavirin (Viramidine)   - 8/10/07

72-week Treatment with Pegylated Interferon plus Ribavirin Can Produce Sustained Virological Response in Some Prior Relapsers    - 6/15/07

Does Attainment of Sustained Virologic Response (SVR) from Treatment of HCV Constitute a Cure?    - 6/01/07

A Follow-up Week 12 Viral Count Is Useful in Predicting SVR and Is 100% Accurate in Patients without Cirrhosis    - 6/01/07

Statins Improve Sustained Response to Interferon-based Therapy in Small Study - 5/25/07

Does Attainment of Sustained Virologic Response (SVR) from Treatment of HCV Constitute a Cure?   - 5/20/07

Selected Patients with Genotype 1 HCV May Attain SVR by Extending Treatment Duration to 72 Weeks  - 4/24/07

Does SVR after Treatment with Pegasys/ribavirin Constitute a Cure for Chronic Hepatitis C?  - 4/20/07

14 Weeks of Treatment with PegIntron plus Ribavirin Is Non-inferior to 24 Weeks in Rapid Responders with HCV Genotype 2 or 3  - 4/20/07

Rapid Virological Response Predicts Sustained Response and Can Help Optimize HCV Treatment  - 4/17/07

Pegylated Interferon/ribavirin Therapy Results in Low SVR Rates after Liver Transplantation in HIV-HCV Coinfected Patients  - 3/27/07

Sustained Response to Interferon Monotherapy Reduces Rates of Liver Cancer and Death in Patients with HCV-related Cirrhosis  - 3/27/07


Sustained Virological Response Improves Fibrosis Progression and Reduces Mortality after Liver Transplantation   2/23/07


HCV Continues to Replicate in the Livers of Patients with Sustained Response to Therapy  12/15/06